!

Geocann Launches Cannabidiol (CBD) Soft Gel Formulations Utilizing Patented Drug Delivery Technology

Condition-specific portfolio showcases cannabis industry first-to-market milestones, including clinically measured bioavailability and science-backed cannabinoid and terpene ratios

FORT COLLINS, Colo. – May 6, 2019 /Canna Newswire/ – Geocann is proud to announce that the company has successfully commercialized the first formulation in a robust portfolio of CBD soft gel products that utilize the multi-patented VESIsorb® delivery system for optimal absorption and measured bioavailability. The formulation is loaded with a science-backed two-to-one ratio of CBD to BCP (beta-caryophyllene) which has been shown to have a synergistic effect as agonists for the CB2, 5-HT1A and glycine receptors.

“This product launch signifies substantial first-to-market milestones for the cannabis industry and further advances Geocann’s leadership position to combine clinically-researched cannabinoids with technologically-advanced innovations that differentiate our formulations with superior therapeutic performance and unmatched supporting science,” said Jesse Lopez, CEO and founder.

The company has developed an impressive vertically integrated system that ensures product quality and consumer safety through rigorously tested starting materials that are formulated with VESIsorb to optimize the performance of the key actives with dramatically improved absorption and bioavailability.

“It is well-known that hemp oil is poorly absorbed in the body,” said Marc Weder, Chief Scientific Officer. “Formulations utilizing VESIsorb ensure that health conscious consumers receive the maximum benefits from key cannabinoids and terpenes, like CBD and BCP. Better absorption leads to higher plasma concentration levels and allows the body to use more of these active ingredients.”

Geocann has worldwide exclusivity for cannabinoids formulated with VESIsorb, and the company is quickly partnering with strategic brand leaders in key channels of distribution to deliver its robust portfolio of patent-protected products, including the recent entry into the European marketplace through Germany.

“We are proud to be the first to deliver a precise and consistent solid dosage form of CBD formulated in a patented delivery system with a 30-year history of safe and effective use. As the consumer demand for bio-enhanced cannabinoid products continues to grow, Geocann is supremely positioned to be the industry’s premier choice for the safest and most efficacious product solutions,” said Lopez.

About Geocann
Geocann is a global cannabis organization led by experienced leadership with scientific and technical expertise for pioneering new innovations in natural health products and solutions. Its focus is combining clinically-researched cannabinoids with technologically-advanced and patented innovations that provide product differentiation with superior therapeutic performance and unmatched supporting evidence. For more information, please visit www.geocann.com.

About VESIsorb
VESIsorb® is the leading delivery system innovation for dramatically improving the bioavailability of poorly absorbed ingredients, like cannabinoids. Since 2005, the advancement and superiority of this colloidal droplet delivery system have consistently been demonstrated in well-designed pilot and peer reviewed published pharmacokinetic absorption and bioavailability studies as well as third-party meta-analyses. For more information, please visit www.vesisorb.com.

# CNW #

Media Contact:
Sam Davidson
sam@geocann.com
+1 (816) 668-8353

   

CBD
Ignite International Brands (U.K.), Ltd. Introduces The United Kingdom To Ignite CBD At London Launch Event And Europe CBD Expo

Ignite UK has now officially launched in the European market with an exciting line up of lifestyle-based CBD products

CBD
PURA Explores CBD Infused Beer With Existing Beer Producer

PURA is a leading CBD infused beverage company having produced over $1 million in CBD Beverages in the United States last year

CBD
KALY Considers Increasing 2019 $20 Million CBD Extraction Revenue Target

KALY is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics in a broad range of disease areas